Drug intelligence / Profile preview

human prostate-specific membrane antigen plasmid DNA vaccine

Development stage
Phase 1
Lead developer
Inovio Pharmaceuticals
Modality
Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intramuscular
01

Overview

A human prostate-specific membrane antigen plasmid DNA vaccine is a therapeutic cancer vaccine consisting of a plasmid encoding the full-length human prostate-specific membrane antigen (PSMA). Upon administration, the encoded PSMA protein is expressed in host cells, stimulating an immune response—primarily T-cell mediated—against cells expressing PSMA. This approach aims to induce both antibody and cytotoxic T-cell responses targeting prostate cancer cells that overexpress PSMA. The primary indication for this investigational therapy is recurrent or advanced prostate cancer. Clinical trials have demonstrated that such vaccines can elicit immunological responses and are generally well tolerated, with most side effects being mild and related to injection site reactions or flu-like symptoms[2][5][6].

Other names
human PSMA plasmid DNA vaccinePSMA DNA vaccine
02

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on human prostate-specific membrane antigen plasmid DNA vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on human prostate-specific membrane antigen plasmid DNA vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call